1 Result: Renalytix
Breaking: Renalytix's KidneyIntelX.dkd FDA-Approved, VSE Secures Up to $565M Contract
June 29th, 2023
Shares of Renalytix plc (Nasdaq: RNLX) surged over 25% in after-hours trading following the company's announcement of receiving De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for its KidneyIntelX.dkd prognostic test.. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Countdown to Earnings: Xylem, Datadog, and Fiserv in Spotlight
February 08th, 2026Biotech Earnings Ahead for Exelixis, Gilead Sciences, Incyte
February 08th, 2026Arch Capital, Dynatrace, Cleveland-Cliffs Headline Earnings Calendar
February 08th, 2026NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026
Member Login